PDF(Pubmed)
Abstract：
Primary cardiac angiosarcoma is a rare malignant soft-tissue sarcoma derived from vascular endothelial cells or lymphatic endothelial cells, with a high malignancy, poor prognosis, and a lack of effective medical therapy. This article reports on two patients with primary cardiac angiosarcoma who received first-line treatment with multi-targeted anti-angiogenic agent, anlotinib monotherapy. The treatment rapidly controlled pleural and pericardial effusion, significantly reduced the tumor, improved symptoms, and showed satisfactory recent efficacy. This indicates that anlotinib offers a new first-line treatment option for advanced primary cardiac angiosarcoma.
摘要：
原发性心脏血管肉瘤是一种罕见的来源于血管内皮细胞或淋巴内皮细胞的恶性软组织肉瘤。恶性程度很高，预后不良,缺乏有效的药物治疗。本文报道了2例原发性心脏血管肉瘤患者接受多靶向抗血管生成药物一线治疗，安洛替尼单药治疗。治疗迅速控制胸膜和心包积液，显著减少了肿瘤，症状改善,近期疗效满意。这表明安洛替尼为晚期原发性心脏血管肉瘤提供了新的一线治疗选择。
